{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "A biased coin design was used for volume assignment."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "This study employed a dose-finding protocol to determine the maximum effective volume of 0.25% ropivacaine required to prevent HDP in 90% of patients (MEV90) undergoing shoulder arthroscopy with ultrasound-guided STB."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study employed a dose-finding protocol to determine the maximum effective volume of 0.25% ropivacaine required to prevent HDP in 90% of patients (MEV90) undergoing shoulder arthroscopy with ultrasound-guided STB."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "MEV90 of 0.25% ropivacaine for ultrasound-guided STB was estimated at 7.6 mL (95% CI: 6.5\u20138.5 mL)."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "All patients except the first one received a LA volume determined by the response observed in the immediately preceding participant."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "The study cohort comprised 52 patients indicated for shoulder arthroscopy finally."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "MEV90 of 0.25% ropivacaine for ultrasound-guided STB was estimated at 7.6 mL (95% CI: 6.5\u20138.5 mL)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: Chinese Clinical Trial Registry (ChiCTR2200059042); first registered 23/04/2022."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 12,
    "max_score": 25
  },
  "model": "gpt-4o"
}